TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24063098
Drug: Alfaxalone 5
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 5 mg/kg
Study: 24063098
Drug: Alfaxalone 10
Normalized name: alfaxalone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 10 mg/kg
Study: 24063098
Drug: Alfaxalone 15
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 15 mg/kg
Study: 24063098
Drug: Alfaxalone 100
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 100 mg/kg
Study: 15160265
Drug: Fluoxetine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine at 20 mg/day for 12 weeks
Study: 11606923
Drug: 0.75% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% metronidazole cream
Study: 11606923
Drug: 1.0% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% metronidazole cream
Study: 7977476
Drug: On-line ST-segment
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-line ST-segment monitoring with sestamibi injection
Study: 238548
Drug: Lorazepam 3
Normalized name: lorazepam 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 3 mg
Study: 238548
Drug: Lorazepam 5
Normalized name: Lorazepam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 5 mg
Study: 238548
Drug: Pentobarbitone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone 50 mg
Study: 24484547
Drug: Lo‐AscA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lo‐AscA (50 mg/kg/24 h, n = 8)
Study: 24484547
Drug: Hi‐AscA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hi‐AscA (200 mg/kg/24 h, n = 8)
Study: 22205317
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (PN) providing 130-150% of resting energy expenditure (REE)
Study: 22205317
Drug: Titrated parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated parenteral nutrition (PN) matched to measured REE
Study: 20807343
Drug: Triamcinolone acetate
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetate 40 mg
Study: 17200359
Drug: Paclitaxel followed
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel followed by FEC chemotherapy with concurrent trastuzumab for 24 weeks
Study: 17200359
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and trastuzumab
Study: 15660042
Drug: Rate-control treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate-control treatment strategy
Study: 15660042
Drug: Rhythm-control treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm-control treatment strategy
Study: 12407485
Drug: Lamivudine 300
Normalized name: lamivudine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 300 mg QD
Study: 10207493
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of hyoscyamine butylbromide
Study: 8527351
Drug: diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diltiazem CD 180 mg
Study: 8527351
Drug: diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem SR 90 mg bid
Study: 28464014
Drug: Perineural 200
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural 200 mg MgSO4 added to 0.25% ropivacaine
Study: 24595550
Drug: TU-100 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU-100 (15 g/day, three times a day)
Study: 23780504
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of lansoprazole 30 mg
Study: 23780504
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of lansoprazole 30 mg
Study: 16439444
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg (IFX/IFX)
Study: 10968529
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active therapy following cast removal
Study: 9578428
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with ganglioside GM2 vaccine (GM2-KLH/QS-21)
Study: 9578428
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with high or low intermediate doses of IFN-alpha2b (10 MU subcutaneously every day, 5 days per week for 4 weeks, followed by either 10 MU subcutaneously, three times weekly for 1 year, or 5 MU subcutaneously, three times weekly for 2 years)
Study: 28841824
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg for 6 weeks
Study: 3084616
Drug: Dihydroergokryptine 2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergokryptine 2, 3, or 4.5 mg
Study: 3084616
Drug: Dihydroergokryptine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergokryptine 2.5 and 5 mg
Study: 3084616
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg iv
Study: 3084616
Drug: Sulpiride 10
Normalized name: sulpiride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 10 mg im
Study: 25715902
Drug: Ultrasound-guided pulsed
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided pulsed radiofrequency treatment (UG-PRF)
Study: 22945782
Drug: Salacia chinensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia chinensis 1000 mg twice-daily
Study: 18650577
Drug: Simplified (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified (single puncture) ilioinguinal and iliohypogastric nerve block with 0.1 ml/kg of 0.25% bupivacaine (Group I)
Study: 18650577
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 1 ml/kg of 0.25% bupivacaine (Group II)
Study: 8765628
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at a dose of 20 to 40 ppm, advanced to 80 ppm if PaO2 remained less than 100 mm Hg (13.3 kPa)
Study: 8765628
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment without NO)
Study: 30049885
Drug: CapOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapOX plus bevacizumab (CapOX/BEV arm: bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m2 on day 1 and oral capecitabine 2,000 mg/m2 on days 1‐14, every 3 weeks)
Study: 30049885
Drug: CapIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapIRI plus bevacizumab (CapIRI/BEV arm: bevacizumab 7.5 mg/kg and irinotecan 200 mg/m2 on day 1 and capecitabine 1,600 mg/m2 on days 1‐14, every 3 weeks)
Study: 27623721
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg tramadol (Group T0.5)
Study: 27623721
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg tramadol (Group T0.25)
Study: 27623721
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.05 ml/kg (Group TNS)
Study: 15670982
Drug: 10 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/day sc-FOS for 5 weeks
Study: 11865814
Drug: TMTX 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMTX 110 mg/m2 followed 24 h later by LV 200 mg/m2/5-FU 500 mg/m2 plus oral LV rescue, given weekly for 6 weeks every 8 weeks.
Study: 11865814
Drug: 5-FU 600
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 600 mg/m2 with LV 200 mg/m2, given weekly for 6 weeks every 8 weeks.
Study: 11865814
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (TMTX/5-FU/LV and 5-FU/LV)
Study: 10836659
Drug: Drospirenone 2
Normalized name: drospirenone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 2 mg/30 microg ethinylestradiol
Study: 10836659
Drug: Drospirenone 3
Normalized name: drospirenone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3 mg/30 microg ethinylestradiol
Study: 10836659
Drug: Drospirenone alone
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone alone (2 mg and 3 mg)
Study: 10836659
Drug: Drospirenone alone
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone alone (0.5 mg, 1.0 mg, 2.0 mg, 3.0 mg)
Study: 2431648
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (30 ml) diluted with 0.9% saline
Study: 2431648
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (30 ml) diluted with dextran 110
Study: 26993105
Drug: Calcitonin nasal
Normalized name: calcitonin nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin nasal spray 200 IU/day once a day for 3 months after surgery
Study: 24884585
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (250 mg daily)
Study: 24884585
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mg of olive oil daily)
Study: 23136909
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (comparator vaccine)
Study: 15996060
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy with adalimumab (7 infusions: Week 0, 2, 4, 6, 8, 10, and 12)
Study: 15996060
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy with adalimumab
Study: 15996060
Drug: Baseline levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline levels of sex hormones in patients with RA
Study: 2013505
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid with metronidazole
Study: 28598899
Drug: venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine ER 75-225 mg/day
Study: 25462210
Drug: Octreotide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (600 μg/24 hours by infusion)
Study: 23458319
Drug: Internet-delivered transdiagnostic
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered transdiagnostic cognitive behavioural therapy (iCBT)
Study: 19438775
Drug: Traditional pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional pump flow rate set on 2.4 L/min/m(2) of body surface area
Study: 9570197
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride 1 mg/min
Study: 7978099
Drug: Ondansetron 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.25 mg bid
Study: 2558365
Drug: Neurokinin A
Normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurokinin A (0.02 ml, 10(‐5)M)
Study: 1201769
Drug: Intravenous fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fat solution containing 40 g of soy bean oil
Study: 1201769
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat solution containing 40 g of soy bean oil
Study: 1201769
Drug: Intraduodenal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal fat solution containing 40 g of soy bean oil
Study: 1201769
Drug: Intravenous, oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous, oral, and intraduodenal fat administration
Study: 30084112
Drug: GEMI/ROSU FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMI/ROSU FDC (gemigliptin 50 mg and rosuvastatin 20 mg)
Study: 30084112
Drug: GEMI (gemigliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEMI (gemigliptin 50 mg)
Study: 30084112
Drug: ROSU (rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROSU (rosuvastatin 20 mg)
Study: 19107051
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of dexamethasone administered intravitreally
Study: 19107051
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and antibiotics (general reference)
Study: 12919154
Drug: Alprazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.02 mg/kg orally at -90 min)
Study: 1342906
Drug: Hydrocortisone 0.1%
Normalized name: HYDROCORTISONE 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 0.1% solution
Study: 1342906
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 1% solution
Study: 1342906
Drug: Piroxicam 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 0.5% solution
Study: 25941207
Drug: Family-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based intervention in grade 6 and school-based drug preventive intervention in grade 7
Study: 25941207
Drug: Family-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based intervention and school-based drug preventive intervention
Study: 22694350
Drug: Lactobacillus reuteri-containing
Normalized name: Lactobacillus reuteri-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri-containing tablets
Study: 20228677
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (16 mmol bolus, 8 mmol/hr infusion for 10 days)
Study: 18771581
Drug: Bimanual group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimanual group therapy (20 min every work day for four weeks)
Study: 15924667
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + Radiotherapy (C + R group)
Study: 14676046
Drug: Rotigotine 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 13.5 mg
Study: 14676046
Drug: Rotigotine 18.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 18.0 mg
Study: 11014414
Drug: High-dose LY293558
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose LY293558 (1.2 mg/kg)
Study: 11014414
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (30 mg)
Study: 11014414
Drug: Low-dose LY293558
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose LY293558 (0.4 mg/kg)
Study: 1620773
Drug: Talking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking therapy
Study: 6375760
Drug: Daunorubicin (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (45 mg/m2 IV on days 1, 2, 3)
Study: 6375760
Drug: Vincristine, prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine, prednisone, and L‐asparaginase alone
Study: 6375760
Drug: Daunorubicin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (in subsequent nonrandomized treatment)
Study: 6375760
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (6-mercaptopurine and methotrexate with periodic reinforcement with vincristine and prednisone)
Study: 22047557
Drug: Ivacaftor (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor (150 mg every 12 hours)
Study: 9781946
Drug: Prolonged chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged chemotherapy
Study: 7529924
Drug: Iloprost treatment
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost treatment (10 micrograms/ml for the first 3 days, then 40 micrograms/ml for the remaining period, applied daily for 8 weeks)
Study: 3296624
Drug: Oxiracetam (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxiracetam (2.4 mg per day)
Study: 28302573
Drug: 50mg caffeine
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg caffeine capsule
Study: 28302573
Drug: Flour (placebo)
Normalized name: Flours
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flour (placebo) capsule
Study: 22240886
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied calcium glycerophosphate (CGP) 10% in an aqueous lotion, applied once daily for 42 days starting at the third postoperative day.
Study: 14675309
Drug: FACT/GOG-Ntx questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: FACT/GOG-Ntx questionnaire for chemotherapy-naive women
Study: 3545106
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and Clindamycin (G/C)
Study: 29552916
Drug: Intermittent low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermittent low-dose urokinase (UK) 10,000 U/kg once a day for 7 days
Study: 29552916
Drug: Alteplase (rt-PA)
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase (rt-PA) 50 mg by intravenous injection within 2 hours of admission
Study: 10701893
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin therapy (IVIG) 2 g/kg bodyweight
Study: 9554161
Drug: Clomiphene 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene 100 mg/day
Study: 9554161
Drug: Clomiphene 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene 150 mg/day
Study: 9554161
Drug: Clomiphene 50
Normalized name: clomiPHENE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene 50 mg/day
Study: 3551011
Drug: intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous atropine + inhaled oxitropium bromide
Study: 3551011
Drug: intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous atropine alone
Study: 3551011
Drug: intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous salbutamol + inhaled salbutamol
Study: 3551011
Drug: intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous salbutamol alone
Study: 29928924
Drug: EDS-FLU (93,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS-FLU (93, 186, or 372 μg)
Study: 29928924
Drug: EDS-FLU (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS-FLU (all doses)
Study: 28160585
Drug: Topical TGO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TGO gel
Study: 11235780
Drug: Forceful saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forceful saline injections (20 ml) with or without prednisolone acetate (125 mg)
Study: 11235780
Drug: Epidural prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural prednisolone acetate (125 mg) alone
Study: 9286184
Drug: Olanzapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (up to 20 mg/day, median exposure 237 days)
Study: 9286184
Drug: Haloperidol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (up to 20 mg/day, median exposure 203 days)
Study: 3764810
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (5000iu two hours before operation and then twelve hourly for seven days)
Study: 3764810
Drug: Subcutaneous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous saline (control group)
Study: 28585761
Drug: Somatic experiencing
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatic experiencing (SE) therapy, 15 weekly sessions.
Study: 25575716
Drug: McGrath® Series
Approvals — FDA: no, EMA: no, PMDA: no
Description: McGrath® Series 5 (McG)
Study: 23458112
Drug: Integrative psychodynamic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative psychodynamic inpatient therapy
Study: 16496492
Drug: EDTA (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA (35 mg/kg)
Study: 11187915
Drug: DCLSG protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLSG protocol ALL-6 (1984-1988) with chemotherapeutic CNS prophylaxis (dexamethasone, i.v. medium dose methotrexate, intrathecal triple therapy) for 116 weeks
Study: 1995934
Drug: Proguanil 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil 100 mg daily
Study: 1995934
Drug: Chlorproguanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil 20 mg twice weekly
Study: 6548940
Drug: Sucralfate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (5 g given in 1-g divided doses)
Study: 17509350
Drug: Tolterodine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (1 mg twice daily) with behavioral modification
Study: 12161484
Drug: raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene 60 mg/d
Study: 12161484
Drug: raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene 120 mg/d
Study: 12161484
Drug: raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: raloxifene 60 mg/d and 120 mg/d
Study: 8700340
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg/day for 12 weeks with hypocaloric diet
Study: 1810616
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with long-leg plaster (group B)